C WorldWide Group Holding A S Has $19.65 Million Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)

C WorldWide Group Holding A S boosted its position in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 27.8% in the first quarter, HoldingsChannel.com reports. The firm owned 381,751 shares of the company’s stock after purchasing an additional 83,001 shares during the period. Biohaven Pharmaceutical accounts for 0.2% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 27th biggest holding. C WorldWide Group Holding A S’s holdings in Biohaven Pharmaceutical were worth $19,649,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Blueshift Asset Management LLC acquired a new position in shares of Biohaven Pharmaceutical in the fourth quarter valued at approximately $306,000. Emerald Mutual Fund Advisers Trust boosted its holdings in shares of Biohaven Pharmaceutical by 2.4% in the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 480,318 shares of the company’s stock valued at $17,762,000 after buying an additional 11,425 shares during the period. Sigma Planning Corp boosted its holdings in shares of Biohaven Pharmaceutical by 13.8% in the fourth quarter. Sigma Planning Corp now owns 14,908 shares of the company’s stock valued at $551,000 after buying an additional 1,807 shares during the period. Pier Capital LLC acquired a new position in shares of Biohaven Pharmaceutical in the first quarter valued at approximately $3,541,000. Finally, Millennium Management LLC boosted its holdings in shares of Biohaven Pharmaceutical by 12.4% in the fourth quarter. Millennium Management LLC now owns 40,439 shares of the company’s stock valued at $1,495,000 after buying an additional 4,448 shares during the period. Hedge funds and other institutional investors own 84.86% of the company’s stock.

Shares of BHVN stock opened at $63.47 on Friday. The firm has a market capitalization of $2.53 billion, a PE ratio of -10.32 and a beta of 0.60. Biohaven Pharmaceutical Holding Co Ltd has a 12 month low of $26.40 and a 12 month high of $64.83.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($1.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.50) by $0.09. During the same quarter in the prior year, the business posted ($2.32) earnings per share. On average, research analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -6.61 EPS for the current year.

In other Biohaven Pharmaceutical news, Director Declan Doogan sold 2,078 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $45.48, for a total transaction of $94,507.44. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Vlad Coric sold 51,962 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $50.15, for a total transaction of $2,605,894.30. The disclosure for this sale can be found here. In the last three months, insiders sold 437,856 shares of company stock worth $22,279,475. 23.90% of the stock is currently owned by insiders.

Several research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday. Piper Jaffray Companies set a $75.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Monday, March 18th. Svb Leerink upped their price target on shares of Biohaven Pharmaceutical from $50.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday, April 23rd. Oppenheimer upped their price target on shares of Biohaven Pharmaceutical from $54.00 to $70.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Finally, Canaccord Genuity upped their price target on shares of Biohaven Pharmaceutical from $46.00 to $89.00 and gave the company a “buy” rating in a report on Monday, April 15th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Biohaven Pharmaceutical has a consensus rating of “Buy” and an average target price of $69.19.

ILLEGAL ACTIVITY WARNING: “C WorldWide Group Holding A S Has $19.65 Million Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)” was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/c-worldwide-group-holding-a-s-has-19-65-million-position-in-biohaven-pharmaceutical-holding-co-ltd-bhvn.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Read More: Fiduciary

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.